Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Vanguard Intermediate Term Corporate Bond ETF (VCIT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Vanguard Intermediate Term Corporate Bond ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.85 (market cap $4.49B), while Vanguard Intermediate Term Corporate Bond ETF trades at $81.79. The key difference: ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Vanguard Intermediate Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| ACAD | VCIT | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | Fixed Income |
52-Week High | $28.06 | $84.82 |
52-Week Low | $20.06 | $81.54 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
VCIT trades at $82.39 with minimal daily movement (+0.06%) amid bearish technical signals from moving averages. The ETF maintains a competitive 0.03% expense ratio and approximately 5.17% SEC yield, positioning it as a cost-effective intermediate-term corporate bond option. Recent dividend distributions of $0.33-$0.34 highlight consistent income generation, though technical indicators show 14 sell signals against 2 buy signals.
Outlook remains cautious due to bearish technical momentum and corporate bond market sensitivity to interest rate changes. The fund's low-cost structure and steady yield appeal to income-focused investors, but potential volatility from Federal Reserve policy shifts presents near-term risk. Current levels near support at $82 require monitoring for breakdown confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →
